 | Up a level |
Bluemcke, B., Baasner, A., Hauke, J., Wappenschmidt, B., Hahnen, E. and Schmutzler, R. (2014). First experiences with the GS Junior 454 in molecular genetic analysis of patients with hereditary breast and ovarian cancer at the Center of Familial Breast and Ovarian Cancer, Cologne. Oncol. Res. Treat., 37. S. 22 - 23. BASEL: KARGER. ISSN 2296-5262
Bluemcke, B., Keupp, K., Larsen, M., Baasner, A., Waha, A., Versmold, B., Driesen, J., Buelow, L., Ernst, C., Wappenschmidt, B., Hahnen, E. and Schmutzler, R. (2018). NGS-based detection of copy number variations in hereditary breast- and ovarian cancer germline diagnostics. Eur. J. Hum. Genet., 26. S. 536 - 538. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5438
Buelow, L., Keupp, K., Richters, L., Pohl, E., Wappenschmidt, B., Zarghooni, V., Reichstein-Gnielinski, S., Maringa, M., Giesecke, J., Rhiem, K., Hahnen, E. and Schmutzler, R. (2017). Low-level gonosomal mosaicism of a de novo BRCA1 gene mutation - The origin of a constitutional mutation in a breast cancer family. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Fasching, P. A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W. D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R. K., Hahnen, E., Untch, M., Burchardi, N., Blohmer, J-U and Loibl, S. (2021). Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann. Oncol., 32 (1). S. 49 - 58. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Harter, P., Baumann, K., Heimbach, A., Reuss, A., Jackisch, C., Hauke, J., Park-Simon, T. W., Richters, L., Hanker, L., Kroeber, S., Pfisterer, J., Gevensleben, H., Schnelzer, A., Dietrich, D., Schneider, S., Kommoss, S., Marme, F., Prieske, K., Schmutzler, R. and Hahnen, E. (2016). Mutations of risk genes for ovarian cancer in consecutive ovarian cancer patients (AGO TR-1 study). Int. J. Gynecol. Cancer, 26. S. 81 - 83. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1525-1438
Hauke, I., Neidhardt, G., Engel, C., Schmutzler, R. K. and Hahnen, E. (2016). Performance of prediction programs on clearly pathogenic or neutral BRCA1/2 missense variants from GC-HBOC. Oncol. Res. Treat., 39. S. 3 - 5. BASEL: KARGER. ISSN 2296-5262
Hauke, J., Becker, A., Schnurbein, G., Neidhardt, G., Weber-Lassalle, N., Wappenschmidt, B., Hahnen, E., Meindl, A. and Schmutzler, R. (2014). RAD51C deletion screening identifies a recurrent gross deletion in breast and ovarian cancer families. Oncol. Res. Treat., 37. S. 96 - 97. BASEL: KARGER. ISSN 2296-5262
Hauke, J., Ernst, C., Fasching, P. A., Jackisch, C., Seither, F., Klare, P., Rhiem, K. E., Schmatloch, S., Huober, J., Stefek, A., Seiler, S., Uleer, C., Doering, G., Schneeweiss, A., Denkert, C., Untch, M., Blohmer, J-U., Schmutzler, R. K., Loibl, S. and Hahnen, E. (2020). Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332). Ann. Oncol., 31. S. S313 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Hauke, J., Hahnen, E., Burges, A., Reuss, A., Gregorio, N. D., El-Balat, A., Richters, L., Hilpert, F., Schmidt, S., Meier, W., Gevensleben, H., Heubner, M., Dietrich, D., Kast, K., Braicu, E., Neunhoeffer, T., Schmutzler, R. K. and Harter, P. (2018). Prevalence of somatic mutations in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1 study). Oncol. Res. Treat., 41. S. 90 - 92. BASEL: KARGER. ISSN 2296-5262
Heimbach, A., Hauke, J., Richters, L., Kroeber, S., Altmueller, J., Becker, C., Thiele, H., Nuernberg, P., Bluemcke, B., Neidhardt, G., Riehm, K., Schmutzler, R. and Hahnen, E. (2016). TruRisk (R) based next-generation sequencing reveals a high prevalence of deleterious ATM mutations in BRCA1/2-negative breast and ovarian cancer families. Oncol. Res. Treat., 39. S. 52 - 53. BASEL: KARGER. ISSN 2296-5262
Heitz, F., Weber-Lassalle, K., Ernst, C., Moellenhoff, K., De Gregorio, N., Hauke, J., Dietrich, D., Borde, J., Jackisch, C., Park-Simon, T-W, Hanker, L. C., Pohl-Rescigno, E., Prieske, K., Kommoss, S., Marme, F., Stingl, J. C., Rita, S., Harter, P. and Hahnen, E. (2022). Chemotherapy-induced mutations in genes of clonal hematopoiesis increase the risk of myeloid neoplasms. Geburtshilfe Frauenheilkd., 82 (10). S. E88 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Herold, N., Bredow, K., Hahnen, E., Wappenschmidt, B., Hauke, J., Wiedemann, R., Waha, A., Bluemcke, B., Pohl-Rescigno, E., Portnicki, M., Rhiem, K. and Schmutzler, R. (2020). Implementation of an educational program and risk-adjusted prevention program for breast and ovarian cancer of the German Consortium for Hereditary Breast- and Ovarian Cancer. Geburtshilfe Frauenheilkd., 80 (6). S. E37 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Herold, N., Bredow, K., Hahnen, E., Wappenschmidt, B., Hauke, J., Wiedemann, R., Waha, A., Bluemcke, B., Portnicki, M., Pohl-Rescigno, E., Rhiem, K., Kast, K., Huebbel, V, Maringa, M., Crombach, G. and Schmutzler, R. (2020). Knowledge-generating Care using the Example of hereditary Breast- and Ovarian Cancer (BC/OC): Evaluation of the comprehensive Care Concept. Geburtshilfe Frauenheilkd., 80 (10). S. E212 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Herold, N., Lichenheldt, F., Hillebrand, V., Wappenschmidt, B., Hahnen, E., Rhiem, K. and Schmutzler, R. K. (2018). Evaluation of prophylactic mastectomy and breast reconstruction in female BRCA1/2 mutation carriers. Oncol. Res. Treat., 41. S. 41 - 42. BASEL: KARGER. ISSN 2296-5262
Keupp, K., Ernst, C., Bluemcke, B., Versmold, B., Waha, A., Driesen, J., Baasner, A., Larsen, M., Buelow, L., Kroeber, S., Altmueller, J., Thiele, H., Nuernberg, P., Wappenschmidt, B., Neidhardt, G., Rhiem, K., Schmutzler, R., Hahnen, E. and Hauke, J. (2018). Next-generation sequencing via TruRisk (R) genepanel reveal high mutation prevalence in additional risk genes in German BRCA1/2-negative breast and ovarian cancer families. Eur. J. Hum. Genet., 26. S. 541 - 543. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5438
Keupp, K., Richters, L., Buelow, L., Kroeber, S., Ernst, C., Bluemcke, B., Versmold, B., Waha, A., Driesen, J., Baasner, A., Altmueller, J., Thiele, H., Nuernberg, P., Wappenschmidt, B., Neidhardt, G., Rhiem, K., Schmutzler, R., Hahnen, E. and Hauke, J. (2017). TruRisk (R) based next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families reveal high mutation prevalence in additional risk genes. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Larsen, M., Bluemcke, J., Bluemcke, B., Ernst, C., Keupp, K., Buelow, L., Altmueller, J., Thiele, H., Nuernberg, P., Hahnen, E. and Schmutzler, R. (2018). Association of MUTYH with familial breast and ovarian cancer. Eur. J. Hum. Genet., 26. S. 540 - 541. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5438
Llop-Guevara, A., Loibl, S., Villacampa, G., Vladimirova, V., Schneeweiss, A., Karn, T., Zahm, D. -m., Herencia-Ropero, A., Jank, P., van Mackelenbergh, M., Fasching, P. A., Marme, F., Stickeler, E., Schem, C., Dienstmann, R., Florian, S., Nekljudova, V., Balmana, J., Hahnen, E., Denkert, C. and Serra, V. (2021). Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Ann. Oncol., 32 (12). S. 1590 - 1597. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Loibl, S., Weber, K. E., Timms, K. M., Elkin, E. P., Hahnen, E., Fasching, P. A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., Salat, C. T., Rezai, M., Blohmer, J. U., Zahm, D. M., Jackisch, C., Gerber, B., Klare, P., Kuemmel, S., Schem, C., Paepke, S., Schmutzler, R., Rhiem, K., Penn, S., Reid, J., Nekljudova, V., Hartman, A-R, von Minckwitz, G. and Untch, M. (2018). Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann. Oncol., 29 (12). S. 2341 - 2348. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Marme, F., Harter, P., Hauke, J., Heitz, F., Reuss, A., Kommoss, S., Heimbach, A., Prieske, K., Richters, L., Burges, A., Neidhardt, G., de Gregorio, N., El-Balat, A., Hilpert, F., Meier, W., Heubner, M., Kast, K., Braicu, I., Hahnen, E. and Schmutzler, R. (2016). Incidence of germline mutations in risk genes including BRCA1/2 in consecutive ovarian cancer (OC) patients (AGO TR-1). Int. J. Gynecol. Cancer, 26. S. 194 - 196. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1525-1438
Neidhardt, G., Hauke, J., Heilmann, S., Hellebrand, H., Surowy, H. M., Klaschik, K., Honisch, E., Gehrig, A., Sutter, C., Rump, A., Bogdanova-Markov, N., Bugert, P., Mangold, E., Steinemann, D., Ramirez, A., Ditsch, N., Arnold, N., Niederacher, D., Burwinkel, B., Thiele, H., Altmueller, I., Nuernberg, P., Engel, C., Wappenschmidt, B., Rhiem, K., Meindl, A., Schmutzler, R. K. and Hahnen, E. (2016). Compelling evidence for FANCM as a breast cancer susceptibility gene. Oncol. Res. Treat., 39. S. 54 - 55. BASEL: KARGER. ISSN 2296-5262
Pohl, E., Borde, J., Hauke, J., Schmidt, S., Weber-Lassalle, K., Ernst, C., Niederacher, D., Arnold, N., Hellebrand, H., Meindl, A., Gehrig, A., Schmidt, G., Dutrannoy, V., Kast, K., Hahnen, E. and Schmutzler, R. (2018). Beyond CHEK2 in breast cancer: Search for additional moderately penetrant risk gene variants by analyzing the oligogenic disease course in CHEK2 mutation carriers. Eur. J. Hum. Genet., 26. S. 535 - 537. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5438
Pohl, E., Schneeweiss, A., Hauke, J., Moebus, V., Furlanetto, J., Denkert, C., Fasching, P. A., Hanusch, C., Tesch, H., Weber-Lassalle, N., Mueller, V., Rhiem, K., Untch, M., Luebbe, K., Lederer, B., Jackisch, C., Nekljudova, V., Schmutzler, R. K., Hahnen, E. and Loibl, S. (2018). Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study. Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Puppe, J., Liu, X., Ratz, L., Bartke, L., van de Ven, M., Vliet, M. H., Wientjes, E., van der Gulden, H., Zevenhoven, J., Hahnen, E., Malter, W., Wessels, L. F. A., Schmutzler, R., Mallmann, P., Reinhardt, C., Linn, S. and Jonkers, J. (2020). Double BRCA1 and BRCA2 inactivation is epistatic in mammary tumorigenesis and treatment response to PARP-inhibition and platinum drugs. Geburtshilfe Frauenheilkd., 80 (10). S. E104 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Rhiem, K., Richters, L., Hahnen, E., Lampe, B., Rezai, M., Goehring, U. -J., Schumacher, C., Kuemmel, S., Ataseven, B. and Schmutzler, R. (2016). Benchmarking of the DKG check list for inclusion criteria of BRCA testing. Oncol. Res. Treat., 39. S. 59 - 60. BASEL: KARGER. ISSN 2296-5262
Richters, L., Schouten, P. C., Park-Simon, T-W., Hauke, J., Hanker, L., Dietrich, D., Pfisterer, J., Krockenberger, M., Kluin, R., Schnelzer, A., du Bois, A., Kommoss, S., Heimbach, A., Schmidt, S., Marme, F., Prieske, K., Linn, S. C., Schmutzler, R. K., Harter, P. and Hahnen, E. (2018). BRCA-like classification in ovarian cancer - Results from the AGO-TR1-trial. Oncol. Res. Treat., 41. S. 85 - 86. BASEL: KARGER. ISSN 2296-5262
Tuechler, A., Remy, R., Dick, J., Ernst, C., Bluemcke, B., Lakeman, I. M. M., van Asperen, C. J., Devilee, P., Bredart, A., Rhiem, K. E., Stoppa-Lyonnet, D., Schmutzler, R. K. and Hahnen, E. (2021). Incorporating genetic and non-genetic risk factors in breast cancer risk prediction for healthy women with non-informative genetic test result. Ann. Oncol., 32. S. S1104 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Waha, A., Versmold, B., Kast, K., Kiechle, M., Ditsch, N., Meindl, A., Niederacher, D., Hahnen, E., Arnold, N., Mundhenke, C., Horvath, J., Bernd, A., Dikow, N., Hauke, J., Wappenschmidt, B., Riess, O., Schott, S., Speiser, D., Faust, U., Sutter, C., Rhiem, K. and Schmutzler, R. K. (2018). Consensus recommendation of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) on the transfer of multigene analysis data into the clinical care program. Oncol. Res. Treat., 41. S. 182 - 183. BASEL: KARGER. ISSN 2296-5262
Weber-Lassalle, K., Weber-Lassalle, K., Borde, J., Weber-Lassalle, N., Klaschik, K., Neidhardt, G., Richters, L., Hauke, J., Hahnen, E. and Schmutzler, R. K. (2018). Germline loss-of-function variants in BARD1 are associated with familial breast cancer. Oncol. Res. Treat., 41. S. 3 - 4. BASEL: KARGER. ISSN 2296-5262
von Minckwitz, G., Timms, K., Untch, M., Elkin, E. P., Hahnen, E., Fasching, P. A., Schneeweiss, A., Salat, C. T., Rezai, M., Blohmer, J-U, Zahm, D-M, Jackisch, C., Gerber, B., Klare, P., Kummel, S., Paepke, S., Schmutzler, R., Chau, S., Reid, J., Hartman, A-R, Nekljudova, V., Weber, K. E. and Loibl, S. (2017). Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445